Management of the adverse events of afatinib : a consensus of the recommendations of the Spanish expert panel . DB08916 is an irreversible ErbB family blocker tyrosine kinase inhibitor ( TKI ) , which has recently been approved for the treatment of patients with P00533 M+ non-small cell lung cancer . As observed with reversible P00533 TKIs , it can induce class-effect adverse events . Appropriate management of afatinib-related adverse events improves quality of life and clinical outcomes in these patients . Here we provide practical recommendations for the prophylaxis and treatment of the most common of these ( e.g. , diarrhea , rash , mucositis and others ) .